CONTINUING MEDICAL EDUCATION (CME) QUESTIONS|
September 17, 2015
Risk-adapted therapy for extranodal NKTCL
CME
Blood (2015) 126 (12): 1517.
Connected Content
A related article has been published:
Nasal NK/T-cell lymphoma: RT, CT, or both
A related article has been published:
Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study
Citation
Risk-adapted therapy for extranodal NKTCL. Blood 2015; 126 (12): 1517. doi: https://doi.org/10.1182/blood-2015-07-661397
Download citation file: